Senior Medical Science Manager (Sr. MSM) - UK
Does Ultragenyx sponsor H-1B visas?
Check real filing data, salaries & approval rates on VisaTalentUSA
Job Description
Position Summary:
ultraimpact – Make a difference for those who need it most
As Senior Medical Science Manager (Sr. MSM), you are responsible for developing and enhancing professional relationships with medical thought leaders involved in various phases of product development, as well as key medical organisations including treatment centres of excellence and established societies and associations in the UK. You provide medical information through scientific exchange in a fair and balanced manner and provide clinical/scientific support to the company. These are field-based services and require professionals with established personal and scientific credibility to interact with thought leaders and centres of excellence. You will support Ultragenyx products in development and commercialised brands in the UK.
How would you rate this job post?
See what other professionals think about this role.
Similar Opportunities
More Openings at Ultragenyx
Medical Science Manager (Germany, Austria, Switzerland) - Ultragenyx Pharmaceutical
Ultragenyx
GermanyUltra Care Liaison (UCL) - Field-Based Role (DACH Team)
Ultragenyx
GermanySenior Director, Development AI Program Management
Ultragenyx
United StatesDirector, AI Workflow Transformation Lead
Ultragenyx
United StatesExplore Top Companies in this Space
Rezolute
Biotechnology / Medical Research / Pharmaceutical
ICON plc
Biotechnology Research / Clinical Research / Pharmaceutical Services / Medical Device Development
Salesloft
Sales Technology / SaaS
Vinmar
Manufacturing / Petrochemicals / Industrial Distribution / Logistics
Ultragenyx
View Company ProfileUltragenyx (operating at ultragenyx.com) is a biopharmaceutical company engineered for developing therapies for people living with rare and ultra-rare genetic diseases. Founded in 2010 by Emil Kakkis and headquartered in Novato, California, Ultragenyx focuses on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward. Under the hood, the company identifies, acquires, develops, and commercializes novel products for treatment of rare and ultrarare diseases. This allows patients and families affected by these diseases to access innovative treatments and improve their quality of life. Backed by significant funding, including a valuation of $271 million in 2020.
Safety First
- Never pay for a job application.
- Do not share sensitive bank info.
- Verify the client before starting work.